Disease · MONDO_0005086

renal cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. renal cell carcinoma. Diseases, record MONDO_0005086. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005086

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: renal cell carcinoma; Open Targets
Open Targets ID: MONDO_0005086; Open Targets
Other names: RCC, hypernephroma, kidney adenocarcinoma, renal cell carcinoma (disease); Open Targets
Disease Ontology: DOID:4450; Disease Ontology
MeSH: D002292; MeSH
Orphanet: ORPHA:217071; Orphanet
Highest stage of its drugs: Approval, for 22 of its 345 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs345

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SUNITINIB	CHEMBL535	Small molecule	Approval	ClinicalTrials.gov and EMA Human Drugs	101	99	98	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	103	98	98	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Approval	EMA Human Drugs	78	76	76	Drugs and targets
SORAFENIB	CHEMBL1336	Small molecule	Approval	EMA Human Drugs and TTD	71	68	68	Drugs and targets
AXITINIB	CHEMBL1289926	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	69	63	63	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Approval	DailyMed and EMA Human Drugs	71	57	57	Drugs and targets
ALDESLEUKIN	CHEMBL1201438	Protein	Approval	TTD	59	57	56	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	62	55	55	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Approval	EMA Human Drugs	55	53	52	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Approval	EMA Human Drugs	46	45	45	Drugs and targets

1 to 10 of 345

See all 345 drugs

Targets377

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	29	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	24	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	23	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2321	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	20	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5159	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	19	Stem cell growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3815	Drugs and targets
PDCD1	Programmed cell death protein 1	16	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	12	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5156	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	10	Tyrosine-protein kinase receptor FLT3 inhibitor	Approval	https://conductscience.org/library/genes/2322	Drugs and targets
TUBA1A	Tubulin	10	Tubulin disrupting agent; Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	10	Tubulin disrupting agent; Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets

1 to 10 of 377

See all 377 targets

Trials801

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 15 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00326898	Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery	Phase 3	1,943	2016-12-12	Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7	SORAFENIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT04076787	Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib		1,769	2019-10-10	Metastatic Renal Cell Carcinoma	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT01120249	S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery	Phase 3	1,545	2024-03-20	Kidney Cancer	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00700258	Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]		1,520	2024-09-23	Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors	AXITINIB, SUNITINIB, TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01968109	An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Phase 1/2	1,482	2026-01-06	Neoplasms by Site	NIVOLUMAB, RELATLIMAB	Its record names the disease	ClinicalTrials.gov
NCT04669366	Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries		1,205	2024-07-19	Kidney Neoplasms	AXITINIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00720941	Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma	Phase 3	1,110	2013-06-17	Carcinoma, Renal Cell	PAZOPANIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT02231749	Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)	Phase 3	1,096	2018-10-16	Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma	IPILIMUMAB, NIVOLUMAB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT02811861	Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma	Phase 3	1,069	2021-09-24	Renal Cell Carcinoma	EVEROLIMUS, LENVATINIB, PEMBROLIZUMAB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT01210482	Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)		1,050	2024-09-25	Renal Cell Carcinoma	TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 801

See all 801 trials

Comparisons in its trials154

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Everolimus vs Placebo: deaths from any cause	139 of 755	151 of 744	1,499	NCT01120249	Trial comparisons
Everolimus vs Placebo: serious adverse events	154 of 740	68 of 723	1,463	NCT01120249	Trial comparisons
Nivolumab + Ipilimumab vs Sunitinib: deaths from any cause	159 of 547	202 of 535	1,082	NCT02231749	Trial comparisons
Nivolumab + Ipilimumab vs Sunitinib: serious adverse events	305 of 547	213 of 535	1,082	NCT02231749	Trial comparisons
Pembrolizumab vs Placebo: deaths from any cause	18 of 496	33 of 498	994	NCT03142334	Trial comparisons
Pembrolizumab vs Placebo: serious adverse events	100 of 488	56 of 496	984	NCT03142334	Trial comparisons
Sunitinib vs Atezolizumab + Bevacizumab: deaths from any cause	270 of 461	263 of 454	915	NCT02420821	Trial comparisons
Sunitinib vs Atezolizumab + Bevacizumab: serious adverse events	169 of 446	191 of 451	897	NCT02420821	Trial comparisons
Avelumab + Axitinib vs Sunitinib: deaths from any cause	284 of 442	296 of 444	886	NCT02684006	Trial comparisons
Avelumab + Axitinib vs Sunitinib: Number of Participants Who Discontinued Treatment Due to Toxicity	136 of 434	65 of 439	873	NCT02684006	Trial comparisons

1 to 10 of 154

See all 154 comparisons in its trials

Papers from its trials546

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42927855	RESULT	1	PubMed
42586114	RESULT	1	PubMed
41801644	RESULT	1	PubMed
41277563	RESULT	1	PubMed
41115468	RESULT	1	PubMed
40180121	RESULT	1	PubMed
39284337	RESULT	1	PubMed
39233312	RESULT	1	PubMed
39167807	RESULT	1	PubMed
38874883	RESULT	1	PubMed

1 to 10 of 546

See all 546 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005086

GET https://conductscience.org/api/diseases/v1/MONDO_0005086/drugs?page=2

API reference For AI assistants